

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
ALK-Abello (itulazax 12 SQ-Bet SLIT)	 All Wales Therapeutics and Toxicology Centre
 Patient/carer groups Allergy UK Anaphylaxis UK Asthma Relief Charity Asthma + Lung UK Asthma Trust for Asthmatic Children European Federation of Allergy and Airways Disease Patients Association NARA – The Breathing Charity Sinus UK SmellTaste South Asian Health Foundation Specialised Healthcare Alliance The Samter's Society 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee
Healthcare professional groups	Scottish Medicines ConsortiumWelsh Government
Association for Respiratory Technology and PhysiologyAssociation of Respiratory Nurse	Possible comparator companies None.
 Specialists British Association of Dermatologists British Paediatric Respiratory Society British Society for Allergy & Clinical Immunology British Thoracic Society ENT UK National Heart and Lung Institute Neonatal and Paediatric Pharmacists Group Primary Care Respiratory Society UK Royal College of General Practitioners 	 Relevant research groups Asthma, Allergy and Inflammation Research Trust British Association for Lung Research Cochrane Airways Group David Hide Asthma and Allergy Research Centre Genomics England MRC Clinical Trials Unit National Institute for Health Research

Provisional stakeholder list for the evaluation of betula verrucosa (itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Paediatrics & Child Health Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	 Associated Public Health groups Public Health Wales UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Provisional stakeholder list for the evaluation of betula verrucosa (itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

Issue date: August 2025





Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.